Opinion|Videos|November 18, 2026

Initial Diagnostic Work-Up for Suspected NETs

Simron Singh, MD, MPH, of Sunnybrook Odette Cancer Centre, and Jonathan R. Strosberg, MD, of Moffitt Cancer Center, walk through the diagnostic work-up for a suspected neuroendocrine tumor (NET) with moderator Daniel M. Halperin, MD, of Winship Cancer Institute of Emory University.

Simron Singh, MD, MPH, of Sunnybrook Odette Cancer Centre, and Jonathan R. Strosberg, MD, of Moffitt Cancer Center, walk through the diagnostic work-up for a suspected neuroendocrine tumor (NET) with moderator Daniel M. Halperin, MD, of Winship Cancer Institute of Emory University. Singh starts with tissue, often reviewed by an experienced NET pathologist, then cross-sectional imaging, a somatostatin receptor (SSTR) scan, and sometimes fludeoxyglucose F 18 (FDG) positron emission tomography (PET) for higher-grade tumors. His center no longer uses chromogranin A because unexpected elevations create uncertainty. Strosberg obtains SSTR PET in almost every patient at baseline and repeats it before peptide receptor radionuclide therapy or surgery, or when disease is best seen on SSTR imaging, and uses FDG PET sparingly. He always checks 5-hydroxyindoleacetic acid in metastatic small bowel NETs to screen for carcinoid heart disease, orders pancreatic hormone levels only when a syndrome is suspected, and sees no need for serotonin testing in pancreatic or rectal NETs.


Related to this article